RXi Pharmaceuticals Corp

Receive alerts
Market Cap:
52 weeks high
52 weeks low

In brief

RXi Pharmaceuticals (Nasdaq: RXII) is a biopharmaceutical company pursuing the development and commercialization of novel treatments for human diseases using a technology called RNA interference (RNAi). RNAi was discovered by our co-founder, Dr. Craig Mello, who was awarded the 2006 Nobel Prize for his groundbreaking work in this area. By harnessing the power of RNAi, we believe that RXi Pharmaceuticals may be able to develop a new class of therapeutic products that could have a number of distinct advantages over today’s drugs.